Assessing direct costs of treating metastatic triple-negative breast cancer in the USA
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Evaluation of monthly cost during metastatic triple-negative breast cancer (mTNBC) treatment. Patients & methods: Retrospective electronic medical record review of US females aged ≥18 years diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Mean monthly costs per patient were evaluated from start of mTNBC treatment until transfer to hospice, end of record or 3 months prior to death. Results: The mean monthly cost of first line was $21,908 for 505 treated patients; 50.2% of cost was attributable to hospitalization and emergency department visits, and 32.7% to anticancer therapy. Similar patterns were observed for subsequent lines of therapy. Conclusion: The majority of costs were attributable to hospitalization and emergency department services, suggesting a need for effective interventions to reduce utilization of costly services.
Lay abstract
This study looked at monthly cost during metastatic triple-negative breast cancer (mTNBC) treatment. Medical records were reviewed for US females aged 18 years or older, diagnosed with mTNBC between January 2010 and January 2016. Average monthly costs per patient were looked at from the start of mTNBC treatment until transfer to end of life care, end of the medical record or 3 months before death. The average monthly cost of first-line treatment was $21,908 for 505 treated patients; about half of this cost was from hospitalization and emergency department visits, and about a third was from anticancer therapy. Similar patterns were seen for subsequent lines of therapy. Most of the costs were from hospitalization and emergency department services, pointing to a need for change to reduce the use of costly services.
Supplementary Material
File (suppl_data.zip)
- Download
- 37.76 KB
References
Papers of special note have been highlighted as: • of interest
1.
Lin NU, Vanderplas A, Hughes ME et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22), 5463–5472 (2012).
• Women diagnosed with triple-negative breast cancer (TNBC) have a worse prognosis than those diagnosed with hormone receptor-positive disease.
2.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
3.
Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J. Clin. Oncol. 28(11), 1958–1962 (2010).
4.
Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 17(3), 173–176 (2010).
5.
Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13(15 Pt 1), 4429–4434 (2007).
6.
Kassam F, Enright K, Dent R et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer 9(1), 29–33 (2009).
7.
Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24(36), 5652–5657 (2006).
8.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Version 4.2020. (2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
• This reference describes current the National Comprehensive Cancer Network treatment guidelines in this population.
9.
Schmid P, Rugo HS, Adams S et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 21(1), 44–59 (2020).
10.
US FDA. VENTANA PD-L1 (SP142) assay - P160002/S009. (2020). https://www.fda.gov/medical-devices/recently-approved-devices/ventana-pd-l1-sp142-assay-p160002s009
11.
Vera-Llonch M, Weycker D, Glass A et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 11, 250 (2011).
• This reference reported the cost of care for women with metastatic breast cancer who received chemotherapy as their principal treatment modality. These patients had no record of receiving concomitant or subsequent hormonal therapy, or receipt of trastuzumab.
12.
Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. Curr. Med. Res. Opin. 28(3), 419–428 (2012).
• This reference reported the cost of TNBC and non-TNBC based on an analysis of claims data. Patients with de novo stage IV TNBC incurred significantly higher costs attributable to inpatient stays than those with de novo stage IV non-TNBC.
13.
Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am. Health Drug Benefits 9(1), 23–32 (2016).
• This reference reported the pattern of cost by stage of disease among all metastatic breast cancers. The pattern of findings showed greater cost for those with advanced disease.
14.
Burton T, Byfield SD, Smith GL et al. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database. Curr. Med. Res. Opin. 32(8), 1417–1423 (2016).
15.
Byfield SD, Buck PO, Blauer-Peterson C et al. ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. J. Oncol. Pract. 12(2), 159–160 (2016).
16.
Pisu M, Azuero A, Meneses K, Burkhardt J, McNees P. Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI). Breast Cancer Res. Treat. 127(2), 521–529 (2011).
17.
Hao Y, Li N, Fang AP et al. Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy. Adv. Ther. 33(6), 983–997 (2016).
18.
Jagsi R, Pottow JA, Griffith KA et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J. Clin. Oncol. 32(12), 1269–1276 (2014).
• This reference reported that patients of minority race appeared to be most vulnerable to financial decline attributable to breast cancer.
Information & Authors
Information
Published In
Pages: 109 - 118
PubMed: 33167695
Copyright
© 2020 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 29 September 2020
Accepted: 23 October 2020
Published online: 10 November 2020
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0213
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Ping Chen, Dan Qiao, Liping Xiao, Guiya Deng, Qing Yang, Rendi Tian, Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US, PLOS ONE, 10.1371/journal.pone.0320727, 20, 4, (e0320727), (2025).
- Matthew J. Monberg, Steve Keefe, Vassiliki Karantza, Konstantinos Tryfonidis, Sarper Toker, Jaime Mejia, Robert Orlowski, Amin Haiderali, Vimalanand S. Prabhu, Gursel Aktan, A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers, Oncology and Therapy, 10.1007/s40487-024-00308-0, 12, 4, (701-734), (2024).
- Christina M. Zettler, Dilanka L. De Silva, Victoria S. Blinder, Mark E. Robson, Elena B. Elkin, Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations , JAMA Network Open, 10.1001/jamanetworkopen.2023.50067, 7, 1, (e2350067), (2024).
- Sadeq Rezaei, Majid Babaei, A systematic literature review on direct and indirect costs of triple-negative breast cancer, Cost Effectiveness and Resource Allocation, 10.1186/s12962-023-00503-2, 21, 1, (2023).
- Luca Boscolo Bielo, Dario Trapani, Giuseppe Curigliano, Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer, Expert Opinion on Pharmacotherapy, 10.1080/14656566.2023.2201372, 24, 7, (789-801), (2023).
- Rachel Jaber Chehayeb, Annette Hood, Xiaoliang Wang, Rebecca Miksad, Sarah Schellhorn Mougalian, Maryam B. Lustberg, Shi-Yi Wang, Rachel A. Greenup, Lajos Pusztai, Natalia Kunst, Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021, JAMA Network Open, 10.1001/jamanetworkopen.2022.44204, 5, 11, (e2244204), (2022).
- Min Huang, Amin Haiderali, Grace E. Fox, Andrew Frederickson, Javier Cortes, Peter A. Fasching, Joyce O’Shaughnessy, Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review, PharmacoEconomics, 10.1007/s40273-021-01121-7, 40, 5, (519-558), (2022).
- Ju-Yi Hsu, Chee-Jen Chang, Jur-Shan Cheng, Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer, Scientific Reports, 10.1038/s41598-021-04316-2, 12, 1, (2022).
- Laura Dormer, Celebrating 10 years of the Journal of Comparative Effectiveness Research, Journal of Comparative Effectiveness Research, 10.2217/cer-2021-0249, 11, 1, (1-6), (2021).
- Hospitalisation drives cost to treat metastatic triple-negative breast cancer, PharmacoEconomics & Outcomes News, 10.1007/s40274-020-7314-3, 867, 1, (17-17), (2020).